Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project
- Author(s)
- Shaw, B; Chung, E; Wellard, C; Yoo, E; Bennett, R; Birks, C; Johnston, A; Cheah, CY; Hamad, N; Simpson, J; Barraclough, A; Ku, M; Viiala, N; Ratnasingam, S; Armytage, T; Cochrane, T; Chong, G; Lee, D; Manos, K; Keane, C; Wallwork, S; Opat, S; Hawkes, EA;
- Details
- Publication Year 2024-04,Volume 5,Issue #2,Page 325-332
- Journal Title
- eJHaem
- Publication Type
- Research article
- Abstract
- Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL) based on positive results of the landmark phase II randomised G029365 trial. However, trial results for many approved novel therapies in RR-DLBCL have not been replicated in routine care cohorts, as RR-DLBCL patient populations are heterogeneous and trial eligibility is increasingly restrictive. We evaluated outcomes from pola ± bendamustine and rituximab in patients with RR-DLBCL enrolled in a compassionate access program with no alternative treatment options identified via the Australasian Lymphoma and Related Diseases Registry according to their eligibility for the original phase II published study. Of 58 eligible patients, 74% met the criteria deeming them ineligible for the G029365 original study at the time of pola's commencement. Median progression-free survival and overall survival in our cohort were 2.3 and 3.5 months, respectively. In contrast to the landmark trial cohort, more of our patients ceased therapy prior to completion, the majority due to progressive disease and only 8/58 received any subsequent treatment. Dismal outcomes in this Australian real-world population demonstrate trial eligibility is challenging to meet, and newer treatments can be difficult to deliver in routine care. Clinically applicable results from therapeutic studies require trial cohorts to reflect representative clinical populations wherever possible, and more research is required to address the benefit of novel agents in the increasing majority who are ineligible for modern studies.
- Publisher
- Wiley
- Keywords
- antibody‐drug conjugates; diffuse large B‐cell lymphoma; immunotherapy; polatuzumab vedotin; relapse; trial eligibility
- Department(s)
- Clinical Haematology
- Publisher's Version
- https://doi.org/10.1002/jha2.870
- Open Access at Publisher's Site
https://doi.org/10.1002/jha2.870- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-18 03:28:04
Last Modified: 2024-07-18 03:32:48